Helen Torley Halozyme Therapeutics, Inc. (HALO) insider trading activity

Helen Torley is PRESIDENT AND CEO of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 666,744 shares of HALO, which is worth approximately $31.3 Million. The most recent transaction as insider was on Nov 29, 2024, when has been sold 10,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 667K

1.48% 3M change

6.91% 12M change

Total Value Held $31.3 Million

Helen Torley Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 29 2024	SELL Bona fide gift	-	10,000 Reduced 1.48%	666,744 Common Stock
Oct 09 2024	SELL Open market or private sale	$530,200 $53.02 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Oct 09 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Oct 08 2024	SELL Open market or private sale	$542,500 $54.25 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Oct 08 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Sep 26 2024	SELL Open market or private sale	$561,000 $56.1 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Sep 26 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Sep 25 2024	SELL Open market or private sale	$563,400 $56.34 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Sep 25 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Sep 24 2024	SELL Open market or private sale	$582,100 $58.21 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Sep 24 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Sep 12 2024	SELL Open market or private sale	$592,000 $59.2 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Sep 12 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Sep 11 2024	SELL Open market or private sale	$590,900 $59.09 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Sep 11 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Sep 10 2024	SELL Open market or private sale	$590,900 $59.09 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Sep 10 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Aug 15 2024	SELL Open market or private sale	$579,500 $57.95 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Aug 15 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Aug 14 2024	SELL Open market or private sale	$573,700 $57.37 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Aug 14 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Aug 13 2024	SELL Open market or private sale	$562,500 $56.25 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Aug 13 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Feb 16 2024	SELL Payment of exercise price or tax liability	$735,068 $36.1 p/Share	20,362 Reduced 2.92%	676,744 Common Stock
Feb 16 2024	BUY Exercise of conversion of derivative security	-	37,884 Added 5.23%	685,814 Common Stock

Also insider at

DGX

QUEST DIAGNOSTICS INC Healthcare

Director

Helen Torley

PRESIDENT AND CEO

Secaucus, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HALO shares.

Notify only if

Value

Insider Trading

Get notified when an Halozyme Therapeutics, Inc. insider buys or sells HALO shares.

Notify only if

Operation

Value

Type

News

Receive news related to HALOZYME THERAPEUTICS, INC.

Track Activities on HALO

Account